Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.

ABSTRACT:

Introduction

Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared with chemotherapy as first-line therapies for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor-activating mutations. This meta-analysis compares gefitinib, erlotinib, afatinib, and chemotherapy.

Methods

Literature search was performed using relevant keywords. Direct and indirect meta-estimates were generated using log-linear mixed-effects models, with random effects for study. Study-to-study heterogeneity was summarized using I statistics and predictive intervals (PIs).

Results

Literature search yielded eight randomized phase 3 clinical trials comparing gefitinib, erlotinib, or afatinib with chemotherapy as first-line therapy in pat

SUBMITTER: Haaland B 

PROVIDER: S-EPMC4219539 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature